Phase 4 N=28 Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache
Postdural Puncture Headache
Primary: Headache Pain Score — 6.67; 2.33 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=158 Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
HIV-1 · HIV Infections · Acquired Immunodeficiency Syndrome
Primary: Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 24 — 96.6; 91.3 percentage of participants — p=0.23
Phase 3 N=307 A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis
Renal Anemia, Chronic
Primary: Percentage of Participants With Hemoglobin (Hb) Response — 94.12; 93.51 percentage of participants — p=<0.0001
Phase 1 N=28 Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds
Normal Female Volunteers
Primary: Identification of the Full Set of Y-chromosome Short Tandem Repeats in Each Bioopsy. — 3; 1; 0; 0 Participants
Phase 2 N=69 To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
Small Cell Lung Cancer
Primary: Tumor Response Rate (RR) — 8; 6; 12; 1 participants
N/A N=225 SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain
Low Back Pain
Primary: Change in ODI From Baseline to 3 Months Post-treatment — -20.5; -15.2 units on a scale — p=0.019
N/A N=20 Advancing the Standard of Care for Pin Site Care
Diabetes Mellitus · Open Reduction External Fixation
Primary: Total Number of Pin Sites — 244 total number of pin sites
N/A N=5,035 Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy
Colon Cancer
Primary: Percentage of GI Clinic Capacity Filled — 99.6; 86.4 percentage of clinic capacity filled — p=<0.0001
N/A N=219 Evaluation of an Investigational Blood Glucose Monitoring System
Diabetes
Primary: Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/-15mg/dL (<75mg/dL) or Within +/-20% (>=75mg/dL) of Laboratory Glucose Method — 218 Blood Glucose…
Phase 1 N=22 A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Multiple Myeloma
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0 participants
N/A N=98 ENHANCE-Efficacy of the Presence of Right Ventricular Apical Pacing Induced Ventricular Dyssynchrony as a Guiding Parameter for Biventricular Pacing in Patients With Bradycardia and Normal Ejection Fraction
Bradycardia
Primary: LVEF — 64.22; 63.14; 59.96 % LVEF — p=0.1734
Phase 2 N=66 N-Acetyl Cysteine in Pathologic Skin Picking
Pathologic Skin Picking · Neurotic Excoriation · Psychogenic Excoriation
Primary: Yale Brown Obsessive Compulsive Scale (YBOCS) Modified for PSP (NE-YBOCS) — 18.8; 17.6; 16.1; 17.3 units on a scale
Phase 3 N=112 Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
Crohn's Disease
Primary: Remission After 8-week of Treatment — 17; 14 Participants — p=0.526
Phase 3 N=802 Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)
HIV Infection
Primary: Percentage of Participants Achieving <40 Copies/mL Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Week 48 — 88.9; 88.3 Percentage of participants
N/A N=120 Specialized Treatment Early in Psychosis (STEP)
Schizophrenia and Disorders With Psychotic Features
Primary: Number of Patients Hospitalized — 25; 14 participants — p=0.018